- What it is: A long-acting analog of amylin, the hormone the body releases with insulin after a meal.
- Research areas: body weight in adults with overweight or obesity (clinical trials), and amylin receptor signaling (mouse work).
- Evidence level: Real human trial data from phase 1, phase 2 and one phase 3 trial with a cagrilintide-only group, plus animal mechanism work. Still investigational.
- The short version: A once-weekly amylin analog with real clinical trial data. Everything here is what happened in study models, not what it does for any person.
What it is
Cagrilintide is a lab-made analog of amylin, a hormone the pancreas releases along with insulin. It is a chain of 37 amino acids with a fatty-acid side chain attached at one end, which its developers added to make it last far longer than natural amylin. It acts through amylin receptors, not GLP-1 receptors.
Specs at a glance. Reference values for the compound named on the label, from PubChem or KEGG. They describe the compound, not a measurement of the vial you receive. Molecular weight is the free base (the peptide alone, without a salt). Synthetic peptides are usually supplied as a salt such as acetate or TFA, and the salt in this vial has not been confirmed.
| Compound | Cagrilintide |
|---|---|
| Sequence | KCNTATCATQRLAEFLRHSSNNFGPILPPTNVGSNTP-NH2 (37 aa), Cys2-Cys7 disulfide, C20 diacid via gamma-Glu on Lys1 |
| Molecular formula | C194H312N54O59S2 |
| Molecular weight | 4409 g/mol (average, free base) |
| CAS number | 1415456-99-3 |
| Reference record | PubChem CID 171397054 |
| Form | Lyophilized (freeze-dried) powder in one sealed vial |
| Vial size | 10 mg per vial |
| Storage (dry powder) | -20°C or colder, long term. Keep the vial sealed and away from light. |
| Lab report | No lab report on file for this compound. All lab reports → |
What the evidence is
Cagrilintide has been given to people in phase 1, phase 2 and phase 3 trials, all in adults with overweight or obesity or in healthy volunteers, plus mechanism work in mice. Trials that tested it together with another compound are summarized on the research page, kept apart from this table.
| Study | Type | Who or what | What was given | What it measured | What it found |
|---|---|---|---|---|---|
| Kruse et al., Journal of Medicinal Chemistry, 2021 | Chemistry and lab testing | A series of lipidated amylin analogs | Not applicable (design study) | Stability and activity of each analog | Cagrilintide was the analog chosen for clinical development as a stable, long-acting version of amylin |
| Lau et al., Lancet, 2021 | Human, phase 2, randomized, double-blind, placebo- and active-controlled | 906 adults with overweight or obesity and no diabetes (706 on cagrilintide) | 0.3, 0.6, 1.2, 2.4 or 4.5 mg once a week, 26 weeks | Change in body weight | Body weight fell more than placebo at every dose, and more than the active comparator drug at the highest dose. Stomach and gut side effects, mostly nausea, were more common than on placebo |
| Garvey et al. (REDEFINE 1), New England Journal of Medicine, 2025 | Human, phase 3a, randomized, double-blind, placebo-controlled | 3,417 adults with overweight or obesity and no diabetes, 302 of them in a cagrilintide-only group | 2.4 mg once a week, 68 weeks, with lifestyle advice in all groups | Change in body weight | The paper’s main result is for the combination. For the cagrilintide-only group, the sponsor’s 2025 conference data reported body weight fell more than placebo |
| Gabe et al., Diabetes, Obesity and Metabolism, 2024 | Human, phase 1, double-blind, placebo-controlled | 105 healthy adults (53 on cagrilintide) | Once a week, raised step by step to 4.5 mg | Heart rhythm (the QT interval on an ECG) | No clinically relevant lengthening of the QT interval against placebo |
| Carvas et al., eBioMedicine, 2025 | Animal | Male mice on a high-fat diet, some bred without two amylin-receptor components (RAMP1 and RAMP3) | Daily for 3 weeks | Body weight, food intake, brain-cell activity | Body weight and early food intake fell in normal mice. Without the two receptor components the effect was weaker |
Last reviewed 2026-09-24. The combination trials, the numbers behind every row above, and what none of it establishes are on the full research summary →
Storage and shipping
This product is on pre-order. It ships as lyophilized powder in a sealed vial. Store the powder frozen at -20°C. US addresses only. Shipping costs and cutoff times →
Questions about Cagrilintide
Is cagrilintide a GLP-1?
No. It is an amylin analog. In mouse work it lowered body weight through amylin receptors, and removing parts of those receptors weakened the effect (Carvas et al., 2025).
Is there human data?
Yes. The trials above ran in adults with overweight or obesity and in healthy volunteers. The phase 3 trials built to test cagrilintide on its own are still under way on ClinicalTrials.gov, so the full standalone record is not published yet.
Is cagrilintide an approved drug?
We found no approval for cagrilintide anywhere. Its developer describes it as investigational, and its phase 3 trials are still running. Etched Research sells cagrilintide as a research compound for laboratory use only. It is not for human use.
Is there a lab report for cagrilintide?
Not yet. No independent lab report is on file for this compound. When one is, it will be listed on the lab reference page.
Shipping, eligibility and what comes in the box: store FAQ →
For research use only. Not for human consumption.



